Effectiveness and Safety of Pharmacopuncture Therapy for Patients with Lumbar Spinal Stenosis

January 8, 2025 updated by: In-Hyuk Ha, KMD, Jaseng Medical Foundation

Effectiveness and Safety of Pharmacopuncture Therapy for Patients with Lumbar Spinal Stenosis : Multicentered, Pragmatic Randomized Controlled, Parallel Grouped Study

This is 1:1 pragmatic randomized controlled trials in a parallel-grouped, multi-centered design that investigated pharmacopuncture therapy for patients with lumbar spinal stenosis, compared to the conservative treatments including physiotherapy and pharmacological treatments.

Study Overview

Detailed Description

This is 1:1 pragmatic randomized controlled trials in a parallel-grouped, multi-centered design that investigated pharmacopuncture therapy for patients with lumbar spinal stenosis, compared to the conservative treatments including physiotherapy and pharmacological treatments. The physician will decide specific location, type, and doses of pharmacopuncture therapy or conservative treatments according to each participants' disease conditions, respectively. The researcher will record concurrently.

Study Type

Interventional

Enrollment (Actual)

98

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Busan, Korea, Republic of
        • Haeundae Jaseng Hospital of Korean Medicine
      • Daejeon, Korea, Republic of, 35262
        • Daejeon Jaseng Hospital of Korean Medicine
    • Bundang-gu
      • Seongnam-si, Bundang-gu, Korea, Republic of, 13601
        • Dongguk University Bundang Oriental Hospital
    • Dongdaemun-gu
      • Seoul, Dongdaemun-gu, Korea, Republic of, 130-701
        • Kyung Hee University Korean Medicine Hospital
    • Gangdong-gu
      • Seoul, Gangdong-gu, Korea, Republic of, 05278
        • Kyung Hee University Korean Medicine Hospital at Gangdong
    • Gangnam-Gu
      • Seoul, Gangnam-Gu, Korea, Republic of, 135-896
        • Jaseng Hospital of Korean Medicine
    • Gyeonggi Province
      • Bucheon, Gyeonggi Province, Korea, Republic of, 14598
        • Bucheon Jaseng Hospital of Korean Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 69 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Diagnosed with lumbar spinal stenosis based on radiology including computed tomography or magnetic resonance imaging.
  2. Clear neurogenic claudication symptoms existed (symptoms aggravated with walking, and alleviated upon resting in lumbar flexion position).
  3. reported radiating leg pain or low back pain (LBP) with intensity of NRS ≥5
  4. Between the age of 19 and 69 years old.
  5. Participants who agreed to participate the study and voluntarily signed the informed consent form.

Exclusion Criteria:

  1. Patients with vascular claudication
  2. Patients with pathologies of non-spinal origin that may cause LBP or radiating leg pain (e.g. spinal tumor, fracture)
  3. Patients with soft tissue pathologies that may cause LBP or radiating leg pain (e.g. tumor, fibromyalgia, rheumatoid arthritis, gout)
  4. Patients with other systemic diseases that may interfere with treatment effect or outcome interpretation
  5. Patients who administrate those prescribed medicine that may interfere with interpretation of the result (e.g. corticosteroids, immunosuppressants, physchotropic drugs)
  6. Patients for whom pharmacopuncture treatment may be inappropriate or unsafe (e.g. hemorrhagic diseases, blood clotting disorders, history of anti-coagulation medicine intake, serious diabetes with risk of infection)
  7. Patients who were treated with one of the following intervention within the past week; medicine that may potentially influence pain such as NSAIDs (nonsteroidal antiinflammatory drugs), pharmacopuncture, or physical therapies.
  8. Pregnant patients or patients planning pregnancy
  9. Patients with medical history of spinal surgery within the past 3 months
  10. Previous participation in other clinical studies within 1 month of current study enrollment, or plans to participate in other clinical studies during participation (including follow-up period) of the current study after study enrollment
  11. Patients unable to fill out study participation consent form
  12. Patients deemed unsuitable for study participation as assessed by the researchers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: pharmacopuncture group
The physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
This is a pragmatic randomized controlled trials, so the physicians will choose pharmacopuncture treatment, including the type and doses, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.
Active Comparator: conservative treatment group
The physicians will choose the type and time of physical therapy and if needed, pharmacological treatment according to participants' conditions.
This is a pragmatic randomized controlled trials, so the physicians will choose conservative treatment, including physiotherapy and pharmacological treatment, according to each participant's conditions. The researcher will record the specific intervention precisely and concurrently.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric rating scale (NRS)
Time Frame: week 13
NRS is a pain scale in which the patients indicates their subjective pain as a whole number from 0 to 10, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'. The NRS of major painful site, which was chosen between low back and radiation pain in lower extremities, will be reported.
week 13

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numeric rating scale (NRS) of low back pain and radiating pain
Time Frame: week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 25, 53
NRS is a pain scale in which the patients indicates their subjective pain as a whole number from 0 to 10, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable'.
week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 25, 53
Visual analogue scale (VAS) of low back pain and radiating pain
Time Frame: week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 25, 53
The patient indicates their pain severity from minimum 0 to maximum 100, which is a higher score means a worse outcome. VAS of low back pain and radiating leg pain will be reported.
week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 25, 53
Walking distance
Time Frame: week 1, 5, 9, 13, 25, 53
Claudication-free walking distance and maximal walking distance will be evaluated.
week 1, 5, 9, 13, 25, 53
Zurich Claudication Questionnaire (ZCQ)
Time Frame: week 1, 5, 9, 13, 25, 53
ZCQ is a lumbar spinal stenosis-specific patient reported outcome, which evaluate the disease severity, functional scale and satisfaction at the treatment.
week 1, 5, 9, 13, 25, 53
Oswestry disability index (ODI)
Time Frame: week 1, 5, 9, 13, 25, 53
ODI is a functional disability questionnaire. The possible range of each item score is 0 to 5. Total score range is 0 (better outcome) to 100 (worse outcome).
week 1, 5, 9, 13, 25, 53
PGIC
Time Frame: week 13, 25, 53
Participants rate the improvement after treatment on a 7-point Likert scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.)
week 13, 25, 53
Short Form-12 Health Survey version 2 (SF-12 v2)
Time Frame: week 1, 5, 9, 13, 25, 53
The SF-12 consists of 12 questions across 8 domains, and higher scores indicate better health-related quality of life.
week 1, 5, 9, 13, 25, 53
EuroQol-5 Dimension (EQ-5D-5L)
Time Frame: week 1, 5, 9, 13, 25, 53
The EQ-5D-5L consists of 5 questions (mobility, self-care, usual activities, pain, anxiety/depression) that ask about the current state of health, and answers each question with 5 likert. (1=I have no problems about, 2=I have slight problems about, 3=I have moderate problems about, 4=I have severe problems about, 5=I am unable to about)
week 1, 5, 9, 13, 25, 53

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: In-Hyuk Ha, KMD, Ph.D, Jaseng Medical Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 13, 2022

Primary Completion (Actual)

January 19, 2024

Study Completion (Actual)

October 28, 2024

Study Registration Dates

First Submitted

February 15, 2022

First Submitted That Met QC Criteria

February 15, 2022

First Posted (Actual)

February 16, 2022

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 8, 2025

Last Verified

October 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Spinal Stenosis

Clinical Trials on pharmacopuncture

Subscribe